Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 269Neoplasms 148Breast Neoplasms 146Colorectal Neoplasms 128Neoplasm Metastasis 96Prostatic Neoplasms 95Multiple Myeloma 94Ovarian Neoplasms 93Lung Neoplasms 88Squamous Cell Carcinoma of Head and Neck 64Pancreatic Neoplasms 64Recurrence 62Endometrial Neoplasms 58Small Cell Lung Carcinoma 52Melanoma 52Stomach Neoplasms 50Leukemia, Lymphocytic, Chronic, B-Cell 48Carcinoma, Renal Cell 47Leukemia, Myeloid, Acute 46Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 40Urinary Bladder Neoplasms 38Triple Negative Breast Neoplasms 38Parkinson Disease 4, Autosomal Dominant Lewy Body 38Head and Neck Neoplasms 38Lymphoma, Large B-Cell, Diffuse 36Carcinoma, Hepatocellular 35Esophageal Neoplasms 32Lymphoma, Follicular 30Colonic Neoplasms 29

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Locally Recurrent Breast Cancer × 30 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡